All News

Early DA-1726 Trial Reports 68% Liver-Fat Reduction

By Sandy Martin•November 19, 2026

In a 19-person early human trial, weekly DA-1726 injections over 16 weeks were reported to lower liver fat by 68%, alongside weight and abdominal-fat loss. If confirmed, the result could be relevant to obesity-related metabolic health.

An experimental weekly injection has produced an encouraging early signal in adults with obesity: after 16 weeks, DA-1726 was reported to reduce liver fat by 68%, with weight and abdominal fat also moving lower. These outcomes are relevant because fat accumulation in the liver and abdomen often accompanies poor metabolic health.

The scale of the study is essential to interpreting the result. An account of the 16-week findings describes 19 otherwise healthy adults with obesity, of whom 15 received DA-1726 and four received placebo. This is human interventional evidence, but the reported liver-fat estimate has not yet been independently established in a peer-reviewed paper or official trial record.

A large change from a very small trial

The 68% reduction is notable, but it is an early efficacy estimate rather than a settled measure of the drug’s effect. With only four people in the placebo arm, differences between individual participants or baseline imbalances can exert substantial influence on a group comparison. A larger sample is needed to produce a more stable estimate and determine how consistently people respond.

Percentage changes in liver fat also require careful definition. A relative reduction from baseline is not the same as a percentage-point decline, and neither means that an equivalent proportion of liver disease has been reversed. A full scientific report would allow assessment of baseline liver-fat levels, the measurement method, placebo-adjusted effects, missing data and the statistical analysis behind the headline figure.

The accompanying reductions in weight and abdominal fat make the result more coherent as a metabolic signal. However, no detailed effect sizes for those outcomes are established in the evidence available here. The 16-week duration also captures an initial response rather than its durability.

A similar published result involved another drug

The reported DA-1726 figure is close to a result already documented for pemvidutide, but the two drugs and studies should not be conflated.

In a randomized, double-blind, placebo-controlled trial of pemvidutide, 171 adults with a BMI of at least 28 and liver-fat content of at least 10% were assigned to one of three weekly doses or placebo for 12 weeks. Participants receiving the 1.8-mg dose had a 68.5% relative reduction in MRI-measured liver fat, compared with 4.4% for placebo. The 95% confidence interval around the pemvidutide estimate ranged from 52.5% to 84.4%.

That peer-reviewed trial shows that a reduction of this general magnitude is not unprecedented for an investigational metabolic drug. It does not verify the DA-1726 finding: pemvidutide is a different GLP-1/glucagon dual agonist, tested in a much larger population selected for elevated liver fat.

The distinction matters particularly because the DA-1726 participants were described as otherwise healthy adults with obesity, rather than as patients recruited for diagnosed metabolic dysfunction-associated steatotic liver disease. Evidence from one group cannot automatically be transferred to the other.

Liver fat can respond alongside weight and abdominal fat

Other clinical trials support the broader premise that metabolic receptor agonists can produce substantial changes in liver fat. In a phase 2 substudy of the GIP/GLP-1/glucagon agonist retatrutide, 98 adults with overweight or obesity and elevated liver fat underwent MRI assessment. After 24 weeks, normal liver-fat levels were reached by 27%, 52%, 79% and 86% of participants receiving ascending doses from 1 mg to 12 mg, compared with none receiving placebo.

Evidence across the wider GLP-1 drug category also provides context for the body-composition findings. A meta-analysis of 13 randomized controlled trials found that GLP-1 receptor agonists reduced visceral fat, subcutaneous fat, body weight and BMI compared with control treatments.

These studies make the reported combination of lower liver fat, abdominal fat and weight biologically and clinically plausible. They do not establish the size of DA-1726’s effect, because findings cannot be assumed to carry across drugs with different pharmacology, doses and trial populations.

Liver-fat content is also an intermediate metabolic measure. A meaningful decline can indicate reduced fat accumulation in the organ, but it is not by itself evidence of improved liver fibrosis or fewer clinical liver events. Those benefits require appropriate outcomes and longer follow-up.

The next trials will determine the signal’s value

For DA-1726, the immediate priority is a larger randomized trial with sufficiently sized treatment and placebo groups, prespecified liver-fat measurements and enough follow-up to assess whether the change persists. Dose-ranging data would help clarify whether the effect increases consistently with exposure, while broader safety monitoring is necessary because a 19-person study cannot define an adverse-event profile.

The early result therefore has no practice-changing implication yet. Its value is as a development signal: a weekly treatment may be affecting several metabolically relevant fat compartments within 16 weeks. If that pattern is reproduced in larger controlled studies with acceptable tolerability, DA-1726 could become a credible candidate for addressing obesity accompanied by excess liver fat.